Anti-Coagulants - Sweden

Sweden

In Sweden, the Anti-Coagulants market is anticipated to witness a significant growth in revenue, with projections indicating a reach of US$144.10m in 2024.
The market is expected to display a steady upward trajectory, with an annual growth rate (CAGR 2024-2028) of 7.73%.
This growth will contribute to a market volume of US$194.10m by 2028.
It is worth noting that, in comparison to other countries globally, United States will generate the highest revenue in the Anti-Coagulants market, with a projected value of US$16,740.00m in 2024.
In Sweden, the market for anti-coagulants is experiencing a shift towards direct oral anticoagulants due to their convenience and reduced need for monitoring.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Sweden, a country located in Northern Europe, has seen a steady growth in the Anti-Coagulants market in recent years.

Customer preferences: The Swedish population is aging, and as a result, the demand for Anti-Coagulants has increased. Additionally, the country has a high prevalence of cardiovascular diseases, which has also contributed to the growth of the Anti-Coagulants market.

Trends in the market: One of the major trends in the Anti-Coagulants market in Sweden is the shift towards direct oral anticoagulants (DOACs) from traditional anticoagulants such as warfarin. DOACs have gained popularity due to their ease of use, fewer side effects, and lower risk of bleeding. This trend is expected to continue as DOACs become more widely available and affordable.Another trend in the market is the increasing use of Anti-Coagulants for stroke prevention in patients with atrial fibrillation. The Swedish healthcare system has implemented guidelines for the use of Anti-Coagulants in these patients, which has led to an increase in the number of prescriptions.

Local special circumstances: Sweden has a well-established healthcare system that provides universal access to healthcare for its citizens. The country also has a strong pharmaceutical industry, which has contributed to the availability of Anti-Coagulants in the market. Additionally, the Swedish government has implemented policies to promote the use of generic drugs, which has made Anti-Coagulants more affordable for patients.

Underlying macroeconomic factors: The Swedish economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has contributed to the availability of Anti-Coagulants in the market. Additionally, the country has a high level of education and healthcare awareness among its population, which has led to increased demand for Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.